Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework

Health Economics Review

Volumn 5, Issue 1, 2015, Pages

  Kotsopoulos, Nikolaos ^a,b   Connolly, Mark P ^a,b   Remy, Vanessa ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Global Market Access Solutions (GMAS)   (Switzerland)

^c SANOFI PASTEUR   (France)

Author keywords

Cost benefit analysis; Fiscal analysis; Germany; Human papillomavirus; Lifetime modelling; Microeconomics; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHILD; CONCEPTUAL FRAMEWORK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FEMALE; GERMANY; GOVERNMENT; HEALTH CARE COST; HUMAN; MALE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; SOCIAL INSURANCE; VACCINATION;

EID: 84971232031     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/s13561-015-0054-6     Document Type: Article

References (34)

1. Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsague X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer. 2012;12:30. doi:10.1186/1471-2407-12-30.
2. Hillemanns P, Breugelmans JG, Gieseking F, Benard S, Lamure E, Littlewood KJ, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76. doi:10.1186/1471-2334-8-76.
3. Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health. 2006;16(2):185–92. doi:10.1093/eurpub/cki163.
4. Heitland W, Schadlich PK, Chen X, Remy V, Moro L. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. J Med Econ. 2013;16(3):364–71. doi:10.3111/13696998.2012.759582.
5. Klussmann JP, Schadlich PK, Chen X, Remy V. Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. Clinico Econ Outcomes Res. 2013;5:203–13. doi:10.2147/CEOR.S43393.
6. Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2(1):19. doi:10.1186/2191-1991-2-19.
7. Colgrove J, Abiola S, Mello MM. HPV vaccination mandates—lawmaking amid political and scientific controversy. N Engl J Med. 2010;363(8):785–91. doi:10.1056/NEJMsr1003547.
8. Burchett HE, Mounier-Jack S, Griffiths UK, Biellik R, Ongolo-Zogo P, Chavez E, et al. New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries. Health Policy Plan. 2012;27 Suppl 2:ii5–16. doi:10.1093/heapol/czs035.
9. WHO. Report on the WHO consultation on the broader economic impact on vaccines and immunization programmes (BEIVIP). 2012.
10. Bundesamt S. Country Statistics. 2008. www.destatis.de. Accessed 9/1/2013 2013.
11. Auerbach J, Kotlikoff L, Leibfritz W. Generational accounting around the world. Chicago: Chicago University Press; 1999.
12. IARC-Globocan. Global Cancer Statistics 2008. 2013.
13. Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis. 2010;10:360. doi:10.1186/1471-2334-10-360.
14. Krebsdaten. Cancer in Germany. 2013. http://www.krebsdaten.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_in_germany_node.html. Accessed 9/19/2013 2013.
15. Maier F. The Persistence of the Gender Wage Gap in Germany. 2007.
16. OECD. Tax Burden in OECD Countries. Paris: OECD; 2011.
17. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer. 2013;13:10. doi:10.1186/1471-2407-13-10.
18. OECD. Health at a Glance: Europe 2012. OECD Publishing. 2012.
19. Commission EU. Investing in health - Commission staff working document. 2013.
20. WHO. WHO Guide to identifying the Economic Consequences of Disease and Injury. 2009.
21. Ngcobo NJ, Cameron NA. The decision making process on new vaccines introduction in South Africa. Vaccine. 2012;30 Suppl 3:C9–13. doi:10.1016/j.vaccine.2012.04.027.
22. Conway M, Rizzuto C, Weiss L. A better way to speed the adoption of vaccines. The McKinsey Quarterly August 2008. Geneva: WHO; 2008.
23. Connolly MP, Topachevskyi O, Standaert B, Ortega O, Postma M. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics. 2012;30(8):681–95. doi:10.2165/11597750-000000000-00000.
24. Goldman D, Michaud P, Lakdawalla D, Zheng Y, Gailey A, Vaynman I. The fiscal consequences of trends in population health. Natl Tax J. 2009;63(2):307–30.
25. Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012;12:878. doi:10.1186/1471-2458-12-878.
26. Meier V, Werding M. Ageing and the welfare state: securing sustainability. Oxford Rev Econ Pol. 2010;26(4):655–73.
27. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9. doi:10.1002/(SICI)1096-9896(199909)189.
28. DeVuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626–36. doi:10.1002/ijc.24116.
29. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. doi:10.1016/S1470-2045(10)70230-8.
30. Kirrander P, Kolaric A, Helenius G, Windahl T, Andren O, Stark JR, et al. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int. 2011;108(3):355–9. doi:10.1111/j.1464-410X.2010.09770.x.
31. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75. doi:10.1158/1055-9965.EPI-04-0551.
32. Munck-Wickland E, Attner P, Nasman A, Hammarstedt L, Ramqvist T, Dalianis T. Epidemisk ökning av tonsill- och tungbascancer. Läkartidningen. 2010;107:26–8.
33. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv. 2006;61(6 Suppl 1):S3–14. doi:10.1097/01.ogx.0000221010.82943.8c.
34. SPMSD. SmPC Gardasil. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf.